276702-20-6

Upstream product

• 276702-19-3 2-hydroxy-3-nitro-6-chlorobenzenesulfonamide 
• 761448-08-2 2-tert-butyl-6-chloro-benzooxazole-7-sulfonic acid amide 

Downstream Products

• 361392-30-5 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(3,5-dimethylisoxazol4-yl)urea 
• 361391-74-4 6-Chloro-2-hydroxy-3-(3-piperidin-4-yl-ureido)-benzenesulfonamide 
• 360789-15-7 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-propylurea 
• 360789-20-4 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-2-methylpentanyl urea 
• 1026699-05-7 N-[4-chloro-2-hydroxy-3-sulfamylphenyl]-N'-(3-tetrahydrofuryl)urea 
• 361391-78-8 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-cyclobutyl urea 
• 360789-19-1 6-Chloro-3-[3-(1-ethyl-propyl)-ureido]-2-hydroxy-benzenesulfonamide 
• 360789-18-0 3-(3-sec-Butyl-ureido)-6-chloro-2-hydroxy-benzenesulfonamide 
• 361391-72-2 6-Chloro-2-hydroxy-3-[3-(2-methyl-cyclopropyl)-ureido]-benzenesulfonamide 
• 361391-79-9 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-cyclopropanyl urea 
• 360789-16-8 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(ethoxycarbonyl)methylurea 
• 276700-56-2 N-[2-Hydroxy-3-aminosulfonyl-4-chlorophenyl]-N'-(2-chlorophenyl)-urea 
• 276700-60-8 N-(2-Hydroxy-3-aminosulfonyl-4-chlorophenyl)-N'-(2-phenoxyphenyl) urea 
• 276700-72-2 N-(2-benzyloxyphenyl)-N'(4-chloro-2-hydroxy-3-aminosulfonylphenyl1) urea 

Relevant academic research and scientific papers

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor

A series of 3-substituted N,N′-diarylureas was prepared and CXCR2 receptor affinities as well as pharmacokinetic properties were examined. A series of 3-substituted N,N′-diarylureas was prepared and the structure-activity relationship relative to CXCR2 re

Il-8 receptor antagonists

This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Il-8 receptor antagonists

This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Il-8 receptor antagonists

This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists

Novell IL-8 compounds and methods of using them are provided.